GlassScriptPhysician profile
Shaveta Malik
NPI 1154632966
$5,597.61
in general payments reported to CMS, 2019-2025
29 companies · $585 in 2025
The $585 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.72 · 2020: $2,749 · 2021: $707 · 2022: $203 · 2023: $575 · 2024: $733 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,674.64 | 2020-2025 | Wegovy |
| Astellas Pharma US INC | $321.88 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $263.12 | 2022-2025 | |
| Agile Therapeutics, INC. | $227.72 | 2021-2023 | Twirla |
| Therapeuticsmd, INC. | $227.43 | 2019-2022 | |
| Exeltis, USA INC. | $223.94 | 2021-2025 | Slynd |
| Pfizer INC. | $172.82 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $164.97 | 2023-2025 | Myfembree |
| Organon LLC | $164.60 | 2021-2025 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $140.08 | 2023-2025 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Exact Sciences Corporation | $92.81 | 2023-2024 | Cologuard Collection Kit |
| Biogen, INC. | $91.31 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $87.26 | 2019-2024 | |
| Abbvie INC. | $80.71 | 2021-2023 | |
| Medtronic, INC. | $74.30 | 2025 | Truclear |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.34 | 2024-2025 | Zepbound, Jardiance |
| Amgen INC. | $67.51 | 2020-2022 | |
| Hologic Sales and Service, LLC | $61.98 | 2020-2025 | Aptima |
| Dexcom, INC. | $58.00 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $52.24 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $46.38 | 2021 | |
| Millicent US INC | $39.08 | 2025 | Femlyv, Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $35.88 | 2021-2023 | Gardasil 9 |
| Avion Pharmaceuticals | $33.86 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.27 | 2021 | |
| Boston Scientific Corporation | $29.40 | 2023 | |
| Shield Therapeutics INC | $27.69 | 2024-2025 | |
| Bio Products Laboratory USA, INC. | $20.58 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaveta Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.